Lucid Diagnostics Inc.
NCM: LUCDLive Quote
About Lucid Diagnostics Inc.
Healthcare
Medical Devices
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
📊 Fundamental Analysis
Lucid Diagnostics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 25.6% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -710.6%, which indicates that capital utilization is currently under pressure.
At a current price of $1.15, LUCD currently sits at the 27th percentile of its 52-week range (Range: $0.95 - $1.70).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$200.93M
Trailing P/E
--
Forward P/E
-6.39
Beta (5Y)
1.25
52W High
$1.70
52W Low
$0.95
Avg Volume
1.32M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App